This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
RadNet (RDNT) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for RadNet (RDNT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
RadNet (RDNT) Q2 Earnings Match Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 0% and 5.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health, Inc. (ASTH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of 5.26% and 9.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ATI Physical Therapy, Inc. (ATIP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy (ATIP) delivered earnings and revenue surprises of 7.60% and 0.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate RadNet (RDNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can RadNet's (RDNT) Service Fee Revenues Help Lift Q2 Earnings?
by Zacks Equity Research
RadNet's (RDNT) Imaging Center segment is likely to have gained from the increased reimbursement from commercial and capitated payors and strong procedure volumes in the second quarter of 2024.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.73% and 0.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
Zacks.com featured highlights include G-III Apparel, RadNet and Hess
by Zacks Equity Research
G-III Apparel, RadNet and Hess are part of the Zacks Screen of the Week article.
Buy These 3 Momentum Stocks Backed by the Driehaus Strategy
by Tirthankar Chakraborty
G-III Apparel Group (GIII), RadNet (RDNT) and Hess (HES) have been selected as the momentum picks for the day using the Driehaus strategy.
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
The Zacks Analyst Blog Highlights CareCloud, DaVita, RadNet, SkyWest and American Express
by Zacks Equity Research
CareCloud, DaVita, RadNet, SkyWest and American Express are included in this Analyst Blog.
New Strong Buy Stocks for June 12th
by Zacks Equity Research
RDNT, ESLT, CLS, LNTH and ASBFY have been added to the Zacks Rank #1 (Strong Buy) List on June 12, 2024.
5 Stocks to Gain as Service Side of the Economy Bounces Back
by Tirthankar Chakraborty
With service sector activity rebounding in recent times, it's worth placing bets on stocks such as CareCloud (CCLD), DaVita (DVA), RadNet (RDNT), SkyWest (SKYW) and American Express (AXP).
RadNet, Inc. (RDNT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
RadNet (RDNT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
3 Reasons Why Growth Investors Shouldn't Overlook RadNet (RDNT)
by Zacks Equity Research
RadNet (RDNT) could produce exceptional returns because of its solid growth attributes.
All You Need to Know About RadNet (RDNT) Rating Upgrade to Strong Buy
by Zacks Equity Research
RadNet (RDNT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RadNet (RDNT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of 177.78% and 2.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
RadNet (RDNT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
RadNet (RDNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will RadNet (RDNT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
RadNet (RDNT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
RadNet (RDNT) Is Up 14.75% in One Week: What You Should Know
by Zacks Equity Research
Does RadNet (RDNT) have what it takes to be a top stock pick for momentum investors? Let's find out.
RadNet (RDNT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
RadNet (RDNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Option Care (OPCH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 10.34% and 2.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Elanco Animal Health Incorporated (ELAN): Can Its 6.2% Jump Turn into More Strength?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.